Free Trial
NASDAQ:CARM

Carisma Therapeutics (CARM) Stock Price, News & Analysis

Carisma Therapeutics logo
$0.84 -0.02 (-2.75%)
(As of 12:20 PM ET)

About Carisma Therapeutics Stock (NASDAQ:CARM)

Key Stats

Today's Range
$0.82
$0.88
50-Day Range
$0.86
$1.11
52-Week Range
$0.80
$3.16
Volume
114,171 shs
Average Volume
337,048 shs
Market Capitalization
$35.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Carisma Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
66th Percentile Overall Score

CARM MarketRank™: 

Carisma Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 333rd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Carisma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Carisma Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Carisma Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.33) to ($1.26) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Carisma Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Carisma Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Carisma Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.00% of the float of Carisma Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Carisma Therapeutics has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Carisma Therapeutics has recently decreased by 18.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Carisma Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Carisma Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.00% of the float of Carisma Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Carisma Therapeutics has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Carisma Therapeutics has recently decreased by 18.33%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Carisma Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Carisma Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for CARM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.57% of the stock of Carisma Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Carisma Therapeutics' insider trading history.
Receive CARM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARM Stock News Headlines

Carisma Therapeutics, Inc. (CARM)
My #1 Pre IPO Trade for 2025 – NAME and TICKER
One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...
Evercore ISI Remains a Buy on Carisma Therapeutics (CARM)
See More Headlines

CARM Stock Analysis - Frequently Asked Questions

Carisma Therapeutics' stock was trading at $2.93 at the start of the year. Since then, CARM shares have decreased by 70.6% and is now trading at $0.8624.
View the best growth stocks for 2024 here
.

Carisma Therapeutics, Inc. (NASDAQ:CARM) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.31). The company earned $3.39 million during the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative trailing twelve-month return on equity of 957.20%.

Carisma Therapeutics' top institutional shareholders include Barclays PLC (1.32%), Barclays PLC (1.32%), Geode Capital Management LLC (0.62%) and Wexford Capital LP (0.08%).

Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Carisma Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
11/07/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
4/07/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CARM
Web
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+711.7%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-86,880,000.00
Net Margins
-314.78%
Pretax Margin
-315.75%

Debt

Sales & Book Value

Annual Sales
$20.27 million
Book Value
$0.66 per share

Miscellaneous

Free Float
36,502,000
Market Cap
$36.01 million
Optionable
No Data
Beta
1.49
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:CARM) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners